TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1420740

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine administered at bedtime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine administered post evening meal
Number of subjects: 12
Study: 3909330

Group type: EXPERIMENTAL
Intervention: Aztreonam plus clindamycin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tobramycin plus clindamycin
Number of subjects: 66
Study: 31473172

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks (2q8)
Number of subjects: 106
Study: 29882843

Group type: EXPERIMENTAL
Intervention: WBE111 (100 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 27418883

Group type: EXPERIMENTAL
Intervention: BCAA (0.17 g/kg), arginine (0.05 g/kg), citrulline (0.05 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24884934

Group type: EXPERIMENTAL
Intervention: Instant Oatmeal (IO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Old-Fashioned Oatmeal (SO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ready-to-Eat Cereal (RTEC)
Number of subjects: 48
Study: 21857372

Group type: EXPERIMENTAL
Intervention: Hydrated exercise (0%-1% of body mass)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dehydrated exercise (-1% to -2% of body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrated resting control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dehydrated exercise
Number of subjects: 10
Study: 20979906

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% normal saline 2 ml
Number of subjects: 100
Study: 18783360

Group type: EXPERIMENTAL
Intervention: Interventional pain therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 15797965

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCOS group with baseline IGT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PCOS group with normal glucose tolerance (NGT) at baseline
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 12147929

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ACE inhibitor/HCTZ combinations
Number of subjects: 89

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 89

Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 10358862

Group type: EXPERIMENTAL
Intervention: Diovan (valsartan) 80 mg/day for 8 weeks, increased to 160 mg/day if needed
Number of subjects: 20
Study: 7866213

Group type: EXPERIMENTAL
Intervention: Stepwise screening
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Couple screening
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 2002
Study: 1782973

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Codeine phosphate 100 mg with quinidine sulphate 50 mg pretreatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 100 mg in PM
Number of subjects: 8

Group type: COMPARATOR
Intervention: Quinidine sulphate 50 mg
Number of subjects: 8
Study: 6113821

Group type: EXPERIMENTAL
Intervention: Drug alone
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Psychotherapy alone
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Psychotherapy plus drug
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Milieu
Number of subjects: 228
Study: 31596793

Group type: EXPERIMENTAL
Intervention: Virtual audit instrument using Google Street View imagery
Number of subjects: 375
Study: 30412277

Group type: EXPERIMENTAL
Intervention: Metoprolol + ILE
Number of subjects: 10

Group type: COMPARATOR
Intervention: ILE
Number of subjects: 10
Study: 28500394

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 25444356

Group type: EXPERIMENTAL
Intervention: Fasting glucose and lipids added to a validated risk prediction tool for GDM
Number of subjects: 222

Group type: COMPARATOR
Intervention: Validated risk prediction tool for GDM
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Adjusted models for GDM diagnosis
Number of subjects: 222
Study: 23715753

Group type: EXPERIMENTAL
Intervention: Insulin degludec 200 units/mL once daily
Number of subjects: 457

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL once daily
Number of subjects: 457
Study: 20660540

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 19270299

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) with community-based promotional activities
Number of subjects: 2240

Group type: COMPARATOR
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) without community-based promotional activities
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) during low transmission season
Number of subjects: 2240
Study: 17171563

Group type: EXPERIMENTAL
Intervention: Fast-track surgery regimen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional surgery regimen
Number of subjects: 50
Study: 15516639

Group type: EXPERIMENTAL
Intervention: Prophylactic oral iron supplementation (2 mg/kg/day)
Number of subjects: 832

Group type: COMPARATOR
Intervention: No iron supplementation (Control)
Number of subjects: 832
Study: 11226441

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 100 microg, repeated once after 6 h if not in active labor
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (two doses of vitamin C after a 6-h interval)
Number of subjects: 96
Study: 9686662

Group type: EXPERIMENTAL
Intervention: Mothers with gestational diabetes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Newborns of mothers with gestational diabetes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group mothers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group newborns
Number of subjects: 20
Study: 8008686

Group type: EXPERIMENTAL
Intervention: LSA/BXO cases (20 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control specimens (12 non‐LSA/BXO balanitis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control specimens (3 controls with clinical features suggestive of LSA/BXO)
Number of subjects: 20
Study: 2663518

Group type: EXPERIMENTAL
Intervention: Tobramycin in combination with ampicillin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ceftazidime in combination with ampicillin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 35
Study: 31254718

Group type: EXPERIMENTAL
Intervention: Sodium nitrite (0.6 mg/kg/h)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 21
Study: 28409508

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg.kg-1 30 minutes before tests)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with starch supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (mean of C1 and C2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Basal without caffeine
Number of subjects: 8
Study: 27966504

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) as an adjunct to scaling and root planing (SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study: 24885101

Group type: EXPERIMENTAL
Intervention: Tailored intervention including education, supervision, and technical support
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 22870302

Group type: EXPERIMENTAL
Intervention: Sodium fluoride solution (5%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sodium fluoride solution (1% or 2%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 40
Study: 20631019

Group type: EXPERIMENTAL
Intervention: Treadmill walking at 75% of maximal heart rate for 75 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sedentary control condition
Number of subjects: 21
Study: 18808624

Group type: EXPERIMENTAL
Intervention: Si‐Wu‐Tang (SWT) 15 g daily for seven consecutive days after cessation of menstrual bleeding
Number of subjects: 49

Group type: COMPARATOR
Intervention: Si‐Wu‐Tang (SWT) 15 g daily as soon as menstrual bleeding is noted
Number of subjects: 49
Study: 16206458

Group type: EXPERIMENTAL
Intervention: Didanosine and/or stavudine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIV+ individuals not currently taking antiretrovirals
Number of subjects: 65

Group type: COMPARATOR
Intervention: HIV- controls
Number of subjects: 65
Study: 11545641

Group type: EXPERIMENTAL
Intervention: Modified visual acuity testing protocol using isolated surrounded HOTV optotypes
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Modified visual acuity testing protocol
Number of subjects: 178
Study: 9058001

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison group (various other therapies including speech therapy and occupational therapy)
Number of subjects: 20
Study: 8271168

Group type: EXPERIMENTAL
Intervention: Amvisc Plus
Number of subjects: 49

Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 49
Study: 2887186

Group type: EXPERIMENTAL
Intervention: Metoprolol (243 +/- 26 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol (149 +/- 16 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 +/- 8 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CWT (Colour Word Test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ORT (Orthostatic Testing)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CPT (Cold Pressor Test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Visual analogue scales for stress and irritation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Self ratings of tiredness
Number of subjects: 15

Group type: COMPARATOR
Intervention: Performance in CWT
Number of subjects: 15
Study: 2919849

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 31162709

Group type: EXPERIMENTAL
Intervention: Optimal designs in three-level cluster randomized trials with a binary outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MaxiMin design
Number of subjects: 0
Study: 28465224

Group type: EXPERIMENTAL
Intervention: Shoe orthotics
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Shoe orthotics plus chiropractic treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Waitlist group (no treatment)
Number of subjects: 225
Study: 26055635

Group type: EXPERIMENTAL
Intervention: 60 min CCT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 90 min CCT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 120 min CCT
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study: 23114033

Group type: EXPERIMENTAL
Intervention: Fluoride followed by laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 23364504

Group type: EXPERIMENTAL
Intervention: Multimodality chest physiotherapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: MH and suctioning (control group)
Number of subjects: 173
Study: 19537524

Group type: EXPERIMENTAL
Intervention: DoloVisano Methocarbamol 750 mg (test product)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Registered reference product (reference product)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of test and reference products
Number of subjects: 32
Study: 16446056

Group type: EXPERIMENTAL
Intervention: Efaproxiral arm
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control arm (WBRT without efaproxiral)
Number of subjects: 515
Study: 15515038

Group type: EXPERIMENTAL
Intervention: 20 min daily exposure to static magnetic fields (4 patients)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 70 min daily exposure to static magnetic fields (7 patients)
Number of subjects: 11
Study: 11290479

Group type: EXPERIMENTAL
Intervention: IV rt-PA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 9335514

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxoid therapy (combination with various chemotherapeutic agents and monoclonal antibodies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxoid monotherapy or combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxoids in randomized adjuvant trials
Number of subjects: 0
Study: 8201963

Group type: EXPERIMENTAL
Intervention: L-phenylalanine (10 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: D-phenylalanine (D-PA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2906873

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ramixotidine 750 mg (CM 57755A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31095060

Group type: EXPERIMENTAL
Intervention: Multicomponent health information technology mental health screening intervention
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Guideline care
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Trauma-informed care
Number of subjects: 390

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 390
Study: 28502786

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Graded Exercise Therapy (GET) for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Education (single visit with clinicians and a booklet)
Number of subjects: 46
Study: 25506778

Group type: EXPERIMENTAL
Intervention: High saturated fat meal (930kcal, 60g fat)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil meal (930kcal, 60g fat)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Participants with a mood disorder history
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Higher levels of hostile behaviors
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison of the two meals
Number of subjects: 43
Study: 22948337

Group type: EXPERIMENTAL
Intervention: Parenting Matters intervention along with usual care
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual Care alone
Number of subjects: 178
Study: 21761129

Group type: EXPERIMENTAL
Intervention: TAC/SRL group (n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: SRL/ST group (n = 21)
Number of subjects: 47
Study: 18320559

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 6 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DRD‐3 polymorphisms in disequilibrium with ser‐9‐gly
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: One DRD‐3 polymorphism not in complete linkage disequilibrium
Number of subjects: 88
Study: 16438763

Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Generic propofol
Number of subjects: 60
Study: 12904191

Group type: EXPERIMENTAL
Intervention: Group L10F25 (10 mg lidocaine plus 25 microg fentanyl)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group L10F25E15 (10 mg lidocaine plus 25 microg fentanyl plus 15 microg epinephrine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group L20F25 (20 mg lidocaine plus 25 microg fentanyl)
Number of subjects: 75
Study: 10946428

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 0
Study: 9049593

Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin (350 mg thrice daily for 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine (1 g thrice daily)
Number of subjects: 0
Study: 8349341

Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 100

Group type: COMPARATOR
Intervention: No traction
Number of subjects: 100
Study: 3519694

Group type: EXPERIMENTAL
Intervention: Isocarboxazid (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocarboxazid
Number of subjects: 0
Study: 30557404

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1,000 IU/day) and Calcium (1,200 mg/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vitamin D3 alone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Calcium alone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 104
Study: 28475205

Group type: EXPERIMENTAL
Intervention: Systemic ELF‐MF therapy (100 microtesla, 1 to 80 Hz)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ELF‐MF therapy
Number of subjects: 37
Study: 23812596

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) 5 mg intravenous once yearly
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study: 22490477

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 100 mg intravenously 15 minutes before incision (PA group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (PA group)
Number of subjects: 60
Study: 21284135

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion monotherapy (switching strategy)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sustained-release bupropion plus citalopram (combination strategy)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Combination regimen
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Switching regimen
Number of subjects: 2
Study: 17391773

Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine combined with Li/DVP
Number of subjects: 0
Study: 12213507

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) treatment programme for 12 weeks
Number of subjects: 135
Study: 10646745

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa with part-time occlusion (3 h/day) for 7 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Levodopa-carbidopa without part-time occlusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison between occlusion and no occlusion groups
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa with part-time occlusion
Number of subjects: 13
Study: 7667054

Group type: EXPERIMENTAL
Intervention: Restricted fluids (65 to 70% of normal maintenance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal maintenance fluids
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Restricted fluids
Number of subjects: 50
Study: 2710502

Group type: EXPERIMENTAL
Intervention: 2% carteolol hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 0
Study: 937076

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 53
Study: 30964970

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Sonicare DiamondClean Smart with Premium Gum Care brush head) in Gum Health mode (DC-GH)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Sonicare DiamondClean Smart with Premium Gum Care brush head) in Clean mode (DC-C)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 188
Study: 28157728

Group type: EXPERIMENTAL
Intervention: VYC-15L
Number of subjects: 225

Group type: COMPARATOR
Intervention: NASHA
Number of subjects: 225
Study: 27009270

Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25010119

Group type: EXPERIMENTAL
Intervention: Intervention condition (small group activities to build coping skills)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 256
Study: 22327702

Group type: EXPERIMENTAL
Intervention: Programmable valves with gravitational units
Number of subjects: 250

Group type: COMPARATOR
Intervention: Programmable valves without gravitational units
Number of subjects: 250
Study: 20184287

Group type: EXPERIMENTAL
Intervention: Emoxipine (150 mg, i.v., daily) for 14 days
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml, i.v., daily) for 14 days
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg, i.v., daily) for 14 days
Number of subjects: 136
Study: 17917897

Group type: EXPERIMENTAL
Intervention: Desk height
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Chair height
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sitting posture analysis
Number of subjects: 101
Study: 16142873

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneous injection twice weekly for 24 weeks
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 12100440

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sulphadoxine/pyrimethamine (SP)
Number of subjects: 142
Study: 10440621

Group type: EXPERIMENTAL
Intervention: Single-dose sparfloxacin (400 mg on day 1)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: 3-day sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for 2 additional days)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: 7-day ciprofloxacin (250 mg twice daily for 7 days)
Number of subjects: 1175